Waypoint Bio
New York, New York, United States · Biotechnology, Health Care, Therapeutics · 21 employees
Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology. The company's platform uniquely combines spatial biology with pooled screening for the purpose of drug discovery, enabling the simultaneous measurement of cell therapy candidates' navigation in the solid tumor microenvironment. Waypoint will use its seed finan
Funding history
- Series series a — $20.0M — May 2026
- Series seed — $14.5M — Jun 2024
Recent signals
- Jun 01, 2026: Waypoint Bio Appoints Dr. Patrick Kaifosh as Chief Technology Officer
- May 27, 2026: Raised $20.0M in Series series a
- Jun 28, 2024: Raised $14.5M in Series seed
See plans & pricing → Track Waypoint Bio’s funding, hiring, and signals — with verified contacts — on Fundz.